This indeed is very good (and much better than I had expected) and it's likely good enough to make this the new SoC for both fit and unfit patients. With the exception of IGHV mutated 17p undeleted fit patients who do extremely well on FCR.
But I expect that a good number of physicians will still stick to FCR in 1L, and not just because of costs. The trial design here is arguably "unfair" - Ibrutinib was used to progression, while FCR was given for six cycles (as it should be). And there is always the camp that wants to sequence chemo upfront while the patient is still fit and able to tolerate it.
Market Data 
Markets 
AI
